Trial Profile
Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Panitumumab (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 05 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Jul 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2025.
- 21 Jul 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2025.